Table 2.
Stem cell source, donor category, and conditioning regimen of studies
| First author [Ref.], year of publication | Stem cell source |
Donor category | Conditioning regimen |
||
|---|---|---|---|---|---|
| alloSCT | autoSCT | alloSCT | autoSCT | ||
| Slovak [1], 2000 | BM | BM | MSD | Bu+Cy | Bu+Cy |
| Suciu [33], 2003 | BM | BM, PB | MSD | Cy+TBI (12 Gy); Bu+Cy | Cy+TBI (12 Gy); Bu+Cy |
| Cho [34], 2013 | BM, PB | PB | MUD, MSD | MAC: Cy+TBI, Bu+Cy, TBI+Ara-C+Mel; RIC: Flu+Bu |
TBI (12 Gy)+Ara-C+Mel |
| Keating [16], 2013 | BM, PB | PB | MSD | NAa | NR |
| Cornelissen [9], 2015 | NR | PB | MSD, MUD | MAC: Cy+TBI (12 Gy), Bu+Cy; RIC: Flu+TBI (2 Gy) |
Bu+Cy |
| Saraceni [32], 2016 | PB, BM | PB | MUD | NR | NR |
| Mizutani [18], 2016 | PB, BM | PB | MSD | NAb | NR |
| Versluis [30], 2017 | PB, BM | PB | MSD | Cy+TBI (12 Gy); Bu+Cy | Bu+Cy |
| Gorin [17], 2017 | PB, BM | PB | MUD | Bu+Cy, Bu+Flu | Bu+Cy, Bu+Mel |
| Mizutani [35], 2017 | BM | PB | MUD | NR | NAc |
| Yao [31], 2017 | PB | PB, BM | MSD, MUD | Bu+Cy+Flu+Ara-C, Bu+Flu+Ara-C |
Bu+Cy+Flu+Ara-C, Bu+Flu+Ara-C |
BM, bone marrow; PB, peripheral blood; MSD, matched sibling donor; MUD, matched unrelated donor; BU, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; Mel, melphalan; Ara-C, cytarabine; Flu, fludarabine; NR, not reported; NA, not applicable.
a
All patients used MAC regimen followed by alloSCT.
b
Either MAC or RIC was used as regimen of alloSCT.
c
In this study, 77% patients received a conditioning regimen containing high-dose cytarabine followed by autoSCT.